Area of research
Oncology · Immunology
Research interest
Research interests include Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, and Epigenetics and DNA Methylation.
Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers
MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes
Pan-Cancer Interrogation of B7-H3 ( <i>CD276</i> ) as an Actionable Therapeutic Target Across Human Malignancies
Genomic, immunologic, and prognostic associations of TROP2 (<i>TACSTD2</i>) expression in solid tumors
The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors
The genomic, transcriptomic, and immunological landscape of TROP2 in solid tumors.
Multiple early factors anticipate post-acute COVID-19 sequelae
IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer
Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy
Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19
Vitamin D deficiency exacerbates UV/endorphin and opioid addiction
Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors
B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma
Epigenetic profiling for the molecular classification of metastatic brain tumors
Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial
miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway
KDM6B Counteracts EZH2-Mediated Suppression of <i>IGFBP5</i> to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer
Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
The RhoJ-BAD signaling network: An Achilles’ heel for BRAF mutant melanomas
B7-H4(B7x)–Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
Lentivirus-induced ‘Smart’ dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma
Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications
Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas